Blueprint Medicines Corp 2024年度报告
Annex 1 Socio-Economic Analysis Of the potential restriction of the perand polyfluoroalkyl substances (PFAS) used in the production, packaging and delivery of human medicinal products
Report of the second joint meeting (hybrid) of the WHO Global Advisory Committee on Vaccine Safety and the WHO Advisory Committee on Safety of Medicinal Products, 14–16 December2022
Clearmind Medicine Inc 2025年年度报告和过渡报告
Position on the Use of Artificial Intelligence in the Medicinal Product Lifecycle
Disc Medicine Inc 2024年度报告
Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
Medicine shortages: EFPIA proposal for action
3D MEDICINES二零二三年中期报告
3D MEDICINES-B二零二二年年报
公众号
小程序
社群